Author

A. Tamin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 4 Organism:human· 3 Assay:proteomics· 2 Research Focus:benchmarking· 1 Organism:chicken / avian· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. Harcourt· 4 shared N. J. Thornburg· 4 shared L. Wang· 3 shared B. Zhou· 2 shared D. Cui· 2 shared D. E. Wentworth· 2 shared G. Bonenfant· 2 shared G. Larson· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

J. Harcourt

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

L. Wang, M. H. Kainulainen, N. Jiang, H. Di, G. Bonenfant, L. Mills, M. Currier, P. Shrivastava-Ranjan, B. M. Calderon, M. Sheth, B. R. Mann, J. Hossain, X. Lin, S. Lester, E. Pusch, , Davis

This study evaluates how well antibodies from mRNA vaccines neutralize SARS-CoV-2 variants, finding that Omicron shows the most escape but booster doses maintain moderate neutralizing activity.

bioRxiv · Nov 24, 2021Microbiology

Surface-aerosol stability and pathogenicity of diverse MERS-CoV strains from 2012 - 2018

N. van Doremalen, M. C. Letko, R. Fischer, T. Bushmaker, K. C. Yinda, J. Schulz, S. N. Seifert, N. J. Kim, M. G. Hemida, G. Kayali, W. B. Park, R. Perera, A. Tamin, N. J. Thornburg, S. Tong, , V. Munster

The paper examines the environmental stability, replication kinetics, and pathogenicity of diverse MERS-CoV strains and SARS-CoV-2, finding variation in stability and pathogenicity among isolates.

bioRxiv · Feb 11, 2021 · PreprintMicrobiology

SARS-CoV-2 susceptibility of cell lines and substrates commonly used in diagnosis and isolation of influenza and other viruses

L. Wang, X. Fan, G. Bonenfant, D. Cui, J. Hossain, N. Jiang, G. Larson, M. Currier, J. Liddell, M. Wilson, A. Tamin, J. Harcourt, J. Ciomperlik-Patton, H. Pang, N. Dybdahl-Sissoko, , B. Zhou

This study evaluates SARS-CoV-2 susceptibility in cell lines used for influenza and other virus diagnosis, finding that some are permissive while others are not, with MDCK cells being insusceptible due to low ACE2 expression.

bioRxiv · Jan 4, 2021Microbiology

Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies

A. P. Chapman, X. Tang, J. R. Lee, A. Chida, K. Mercer, R. E. Wharton, M. H. Kainulainen, J. L. Harcourt, R. B. Martines, M. Schroeder, L. Zhao, A. Bryksin, B. Zhou, E. Bergeron, B. C. Bollweg, , J. M. Goldstein

This study develops and characterizes high-affinity mouse monoclonal antibodies against SARS-CoV-2, showing their neutralizing and diagnostic potential.

bioRxiv · Oct 13, 2020Immunology

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

T. P. Sheahan, A. C. Sims, S. Zhou, C. Hill, S. R. Leist, A. Schaefer, M. Agostini, A. Pruijssers, A. J. Brown, G. Bluemling, M. Natchus, M. Saindane, A. Kolykhalov, G. Painter, R. Swanstrom, , R. S. Baric

This study demonstrates that the antiviral NHC/EIDD-2801 inhibits SARS-CoV-2 and multiple coronaviruses, showing therapeutic efficacy and oral bioavailability in mice.

bioRxiv · Mar 19, 2020 · PreprintMicrobiology

Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient

J. Harcourt, A. Tamin, X. Lu, S. Kamili, S. Kumar Sakthivel, L. Wang, J. Murray, K. Queen, B. Lynch, B. Whitaker, Y. Tao, C. Paden, J. Zhang, Y. Li, A. Uehara, , N. J. Thornburg

The paper isolates and characterizes SARS-CoV-2 from the first US COVID-19 patient, showing high replication in Vero cells and depositing the strain for public use.

bioRxiv · Mar 2, 2020 · PreprintMicrobiology